A Phase 2 interventional study of Apelin and Relaxin in Cardiovascular Diseases and Type 2 Diabetes Mellitus, sponsored by Cambridge University Hospitals NHS Foundation Trust. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Cambridge University Hospitals NHS Foundation Trust · Phase 2, Interventional, and Other
Type two diabetes mellitus (T2DM) is a common, long term metabolic disorder characterised by hyperglycaemia (high blood glucose) resulting from insulin resistance and relative insulin insufficiency. The risk of developing insulin resistance and subsequently T2DM is increased by being overweight and also through a sedentary lifestyle. As the onset can be gradual, physiological damage may have occurred prior to diagnosis. Diabetes is associated with the development of microvascular complications (diabetic nephropathy, neuropathy, and retinopathy), and macrovascular complications (coronary artery disease, peripheral arterial disease, and stroke). While there are many treatments available for T2DM, these complications may still arise, leading to significant morbidity and mortality. There is therefore an urgent need to identify novel signalling pathways that may contribute to the development of diabetes related complications. The identification of these pathways may ultimately lead to the development of new therapies targeting better blood glucose control and preventing these subsequent complications.
Both animal and human studies have indicated that two endogenous peptides, apelin and relaxin both act as vasodilators in the human cardiovascular system and could also have beneficial action in T2DM. Therefore, we aim to carry out experimental medicine studies to test this hypothesis, and explore the signalling pathway in the human vascular system.
An extensive body of evidence demonstrates a direct association between T2DM and cardiovascular complications and mortality. Unfortunately, current therapies for diabetes have failed to be translated into improvements in cardiovascular outcomes, highlighting an urgent need to develop novel therapeutic strategies that can ultimately achieve the dual outcome of improving glycaemic control and improving cardiovascular function.
While the precise cellular mechanisms involved remain to be elucidated, we hypothesise that the apelin and relaxin pathways meet these two criteria and therefore are potential therapeutic targets in conditions of abnormal glucose metabolism and heart failure.
Apelin and relaxin are safe for parenteral use as they are naturally occurring peptide hormones, have a short half-life and will be rapidly cleared. They target endogenous receptors and post-receptor signalling, and have been used in human trials without any significant side effects reported.
5,368 studies on the registry are indexed under Cardiovascular Diseases; 939 are open to participants now.
This study's planned enrollment of 170 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Cambridge University Hospitals NHS Foundation Trust is the lead sponsor of 171 studies on the registry; 37 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy participants
Overweight/obese participants
Participants with type 2 diabetes mellitus
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In sub-study 1A Healthy participants will receive systemic infusions of Apelin to establish a dose range
Drug: Apelin
In sub-study 1B , individuals with Type 2 Diabetes and individuals with increase weight will receive systemic infusions of Apelin or Normal Saline
Drug: Apelin · Drug: Normal saline
In sub-study 2A Healthy participants will receive intra-arterial infusions of Relaxin
Drug: Relaxin · Drug: Normal saline
In sub-study 2B Healthy participants will receive intra-arterial infusions of Relaxin followed by verapamil (on a background infusion of either LN Monomethyl Arginine or Normal Saline, to test effects on nitric oxide)
Drug: Relaxin · Diagnostic Test: Verapamil · Diagnostic Test: LN Monomethyl arginine
In sub-study 3A Healthy participants will receive intra-arterial infusions of Relaxin (background infusion apelin/Normal Saline)
Drug: Apelin · Drug: Relaxin · Drug: Normal saline
In sub-study 3B Healthy participants will receive intra-arterial infusions of Apelin (background infusion Relaxin/Normal Saline)
Drug: Apelin · Drug: Relaxin · Drug: Normal saline
In sub-study 4 Healthy participants, Individuals with Type 2 Diabetes and Individuals with increase weight will receive systemic infusions of Normal saline, Relaxin, Apelin and relaxin
Drug: Apelin · Drug: Relaxin
In sub-study 5 Healthy participants will be allocated to 1 of 4 Relaxin dosing groups and will receive dorsal hand vein infusion of 3 incremental doses of Normal Saline/ D5W and Relaxin
Drug: Relaxin · Drug: Normal saline
Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.
Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.
Also known as: RLX
Vehicle
Also known as: Saline
NO independent challenge agent
Basal NO synthase inhibitor
Also known as: LNMMA
Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin (Glucose)
Glucose, in mmol/l
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin (C-Peptide)
C-peptide, in pmol/L
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin (Glucagon)
Glucagon, in pg/ml
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin (Insulin)
Insulin, in pmol/L
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin (TNF-alpha)
TNF-alpha, in pg/ml
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants
Glucose, in mmol/l
Time frame: Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants
C-peptide, in pmol/L
Time frame: Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants
Glucagon, in pg/ml
Time frame: Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants
Insulin, in pmol/L
Time frame: Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants
TNF-alpha, in pg/ml
Time frame: Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 2a: Change in forearm blood flow parameters in healthy participants after infusion of relaxin (Absolute Flow)
Absolute flow in the infused arm, in mg/dL/min
Time frame: Within visit 2, over a period of up to 4 weeks
Sub-study 2a: Change in forearm blood flow parameters in healthy participants after infusion of relaxin (Percentage Change)
Percentage change in the infused arm, in %
Time frame: Within visit 2, over a period of up to 4 weeks
Sub-study 2a: Change in forearm blood flow parameters in healthy participants after infusion of relaxin (Ratio)
Ratio, expressed as a number (no units as this is a ratio)
Time frame: Within visit 2, over a period of up to 4 weeks
Sub-study 2b: Change in forearm blood flow parameters in healthy participants after infusion of relaxin in the presence of L-NMMA or normal saline
Ratio; absolute flow and percentage change in the infused arm
Time frame: Visit 2 to visit 3, over a period of up to 10 weeks
Sub-study 2b: Change in forearm blood flow parameters in health participants after infusion of verapamil in the presence of L-NMMA or normal saline (Ratio)
Ratio; expressed as a number (no units as this is a ratio)
Time frame: Visit 2 to visit 3, over a period of up to 10 weeks
Sub-study 2b: Change in forearm blood flow parameters in health participants after infusion of verapamil in the presence of L-NMMA or normal saline (Absolute Flow)
Absolute flow in the infused arm, in mg/dL/min
Time frame: Visit 2 to visit 3, over a period of up to 10 weeks
Sub-study 2b: Change in forearm blood flow parameters in health participants after infusion of verapamil in the presence of L-NMMA or normal saline (Percentage Change)
Percentage change in the infused arm, In %
Time frame: Visit 2 to visit 3, over a period of up to 10 weeks
Sub-Study 3a: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial relaxin in the presence of apelin
Ratio; absolute flow and percentage change in the infused arm
Time frame: Visit 2 to visit 3, over a period of up to 10 weeks
Sub-Study 3a: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial relaxin in the presence of apelin (Ratio)
Ratio, expressed as a number (no units as this is a ratio)
Time frame: Visit 2 to visit 3, over a period of up to 10 weeks
Sub-Study 3a: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial relaxin in the presence of apelin (Absolute Flow)
Absolute flow in the infused arm, in mg/dL/min
Time frame: Visit 2 to visit 3, over a period of up to 10 weeks
Sub-Study 3a: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial relaxin in the presence of apelin (Percentage Change)
Percentage change in the infused arm, In %
Time frame: Visit 2 to visit 3, over a period of up to 10 weeks
Sub-Study 3b: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial apelin in the presence of relaxin (Ratio)
Ratio, expressed as a number (no units as this is a ratio)
Time frame: Visit 2 to visit 3, over a period of up to 10 weeks
Sub-Study 3b: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial apelin in the presence of relaxin (Absolute Flow)
Absolute flow in the infused arm, in mg/dL/min
Time frame: Visit 2 to visit 3, over a period of up to 10 weeks
Sub-Study 3b: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial apelin in the presence of relaxin (Percentage Change)
Percentage change in the infused arm, In %
Time frame: Visit 2 to visit 3, over a period of up to 10 weeks
Sub-study 4: Changes in markers of glucose homeostasis healthy participants, participants with increased weight and participants with type 2 diabetes mellitus after infusion of relaxin with and without apelin (Glucose)
Glucose, in each of the groups, in mmol/L
Time frame: Visit 2 to Visit 4, over a period of up to 8 weeks
Sub-study 4: Changes in markers of glucose homeostasis healthy participants, participants with increased weight and participants with type 2 diabetes mellitus after infusion of relaxin with and without apelin (C-peptide)
C-peptide, in each of the groups, in pmol/L
Time frame: Visit 2 to Visit 4, over a period of up to 8 weeks
Sub-study 4: Changes in markers of glucose homeostasis healthy participants, participants with increased weight and participants with type 2 diabetes mellitus after infusion of relaxin with and without apelin (Glucagon)
glucagon, in each of the groups,in pg/ml
Time frame: Visit 2 to Visit 4, over a period of up to 8 weeks
Sub-study 4: Changes in markers of glucose homeostasis healthy participants, participants with increased weight and participants with type 2 diabetes mellitus after infusion of relaxin with and without apelin (Insulin)
Insulin, in each of the groups, in pmol/L
Time frame: Visit 2 to Visit 4, over a period of up to 8 weeks
Sub-study 4: Changes in markers of glucose homeostasis healthy participants, participants with increased weight and participants with type 2 diabetes mellitus after infusion of relaxin with and without apelin (TNF-alpha)
TNF-alpha, in each of the groups, in pg/ml
Time frame: Visit 2 to Visit 4, over a period of up to 8 weeks
Sub-study 5: Change in hand vein diameter after relaxin infusion in healthy participants
Hand vein Demeter is measured using Aellig dorsal hand vein technique
Time frame: Visit 2
Sub-study 1a: Changes in parameters of cardiovascular haemodynamics in healthy participants after infusion of apelin (Echocardiography)
Cardiac output measured by Echocardiography, in L/min
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1a: Changes in parameters of cardiovascular haemodynamics in healthy participants after infusion of apelin (Innocor)
Cardiac output measured by Innocor, in L/min
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1a: Changes in parameters of cardiovascular haemodynamics in healthy participants after infusion of apelin (Bioimpedance)
Cardiac output measured by bioimpedance, in L/min
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin (Echocardiography)
Cardiac output measured by Echocardiography, in L/min
Time frame: VIsit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin (Innocor)
Cardiac output measured by Innocor, in L/min
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin (Bioimpedance)
Cardiac output measured by bioimpedance, in L/min
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin,after a mixed meal challenge (Echocardiography)
Cardiac output measured by Echocardiography, in L/min
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin, after a mixed meal challenge (Innocor)
Cardiac output measured by Innocor, in L/min
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin,after a mixed meal challenge (Bioimpedance)
Cardiac output measured by bioimpedance, in L/min
Time frame: VIsit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge (Clugose)
Glucose, in mmol/L
Time frame: Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge (C-peptide)
C-peptide, in pmol/L
Time frame: Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge (Glucagon)
Glucagon, in pg/ml
Time frame: Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge (Insulin)
Insulin, in pmol/L
Time frame: Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge (TNF alpha)
TNF alpha, in pg/ml
Time frame: Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 2b: Change in forearm blood flow parameters after infusion of verapamil in the presence of L-NMMA or saline (Ratio)
Ratio,expressed as a number (no units as this is a ratio)
Time frame: Visit 2 to visit 3, over a period of up to 10 weeks
Sub-study 2b: Change in forearm blood flow parameters after infusion of verapamil in the presence of L-NMMA or saline (Absolute Flow)
Absolute flow in the infused arm, in mg/dL/min
Time frame: Visit 2 to visit 3, over a period of up to 10 weeks
Sub-study 2b: Change in forearm blood flow parameters after infusion of verapamil in the presence of L-NMMA or saline (Percentage Change)
Percentage change in the infused arm, In %
Time frame: Visit 2 to visit 3, over a period of up to 10 weeks
Sub-study 4: Change in cardiovascular haemodynamics after infusion of relaxin (Echocardiography)
Cardiac output measured by Echocardiography, in L/min
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in cardiovascular haemodynamics after infusion of relaxin (Bioimpedance)
Cardiac output measured by bioimpedance, in L/min
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in cardiovascular haemodynamics after infusion of relaxin (Innocor)
Cardiac output measured by Innocor, in L/min
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in cardiovascular haemodynamics after combined infusion of relaxin and apelin (Echocardiography)
Cardiac output measured by Echocardiography, in L/min
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in cardiovascular haemodynamics after combined infusion of relaxin and apelin (Bioimpedance)
Cardiac output measured by bioimpedance, in L/min
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in cardiovascular haemodynamics after combined infusion of relaxin and apelin (Innocor)
Cardiac output measured by Innocor, in L/min
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (Glucose)
Glucose, in mmol/L
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Substudy 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (C-peptide)
C-peptide, in pmol/L
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (Glucagon)
Glucagon, in pg/ml
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (Insulin)
Insulin, in pmol/L
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (TNF alpha)
TNF alpha, glucose homeostasis
Time frame: Visit 2 to visit 4, over a period of up to 8 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2018 (actual). Primary completion is estimated for Dec 2026, 105 months after the start.
Of 60 non-industry phase 2 interventional studies under Cardiovascular Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 62. This study's planned 105 months is above that.
Counting every sponsor, half of 84 studies reached it within 28 months; a quarter within 16 and three quarters within 59.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Sep 2025 → Dec 2026 and completion Sep 2025 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Apelin · Relaxin
Cambridge University Hospitals NHS Foundation Trust →